Antiviral Responses following L-Leucyl-L-Leucine Methyl Esther (LLME)-Treated Lymphocyte Infusions: Graft-versus-Infection without Graft-versus-Host Disease 

Slides:



Advertisements
Similar presentations
Engineering Human Peripheral Blood Stem Cell Grafts that Are Depleted of Naïve T Cells and Retain Functional Pathogen-Specific Memory T Cells  Marie Bleakley,
Advertisements

Immune Reconstitution in Recipients of Photodepleted HLA-Identical Sibling Donor Stem Cell Transplantations: T Cell Subset Frequencies Predict Outcome 
Cytomegalovirus Viral Load and Virus-Specific Immune Reconstitution after Peripheral Blood Stem Cell versus Bone Marrow Transplantation  Abraham Guerrero,
The Effect of the Composition of Unrelated Donor Bone Marrow and Peripheral Blood Progenitor Cell Grafts on Transplantation Outcomes  Nancy H. Collins,
Apoptotic Donor Leukocytes Limit Mixed-Chimerism Induced by CD40-CD154 Blockade in Allogeneic Bone Marrow Transplantation  Jian-ming Li, John Gorechlad,
Vaccination of Children following Allogeneic Stem Cell Transplantation
In Vivo T Cell Costimulation Blockade with Abatacept for Acute Graft-versus-Host Disease Prevention: A First-in-Disease Trial  Divya T. Koura, John T.
Early Cytomegalovirus Reactivation Leaves a Specific and Dynamic Imprint on the Reconstituting T Cell Compartment Long-Term after Hematopoietic Stem Cell.
Patient HLA-DP–Specific CD4+ T Cells from HLA-DPB1–Mismatched Donor Lymphocyte Infusion Can Induce Graft-versus-Leukemia Reactivity in the Presence or.
Altered Homeostasis of CD4+ Memory T Cells in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Chronic Graft-versus-Host Disease Enhances T Cell.
Effects of the NK Cell Recovery on Outcomes of Unmanipulated Haploidentical Blood and Marrow Transplantation for Patients with Hematologic Malignancies 
Donor-Derived Natural Killer Cells Infused after Human Leukocyte Antigen– Haploidentical Hematopoietic Cell Transplantation: A Dose-Escalation Study  Inpyo.
Combined CD4+ Donor Lymphocyte Infusion and Low-Dose Recombinant IL-2 Expand FOXP3+ Regulatory T Cells following Allogeneic Hematopoietic Stem Cell Transplantation 
Treatment of Adenovirus Disease in Stem Cell Transplant Recipients with Cidofovir  Dionissios Neofytos, Ambrish Ojha, Bijoyesh Mookerjee, John Wagner,
R. Handgretinger, X. Chen, M. Pfeiffer, M. Schumm, I. Mueller, T
Mixed T Cell Chimerism After Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia Using an Alemtuzumab-Containing Regimen Is.
Impact of Serotherapy on Immune Reconstitution and Survival Outcomes After Stem Cell Transplantations in Children: Thymoglobulin Versus Alemtuzumab  Laura.
Overlap between in vitro donor antihost and in vivo posttransplantation TCR Vβ use: a new paradigm for designer allogeneic blood and marrow transplantation.
Busulfan, Fludarabine, and Alemtuzumab As a Reduced Toxicity Regimen for Children with Malignant and Nonmalignant Diseases Improves Engraftment and Graft-versus-
Long-Term Immune Reconstitution of Naive and Memory T Cell Pools after Haploidentical Hematopoietic Stem Cell Transplantation  Rita I. Azevedo, Maria.
Reconstitution of Natural Killer Cells in HLA-Matched HSCT after Reduced-Intensity Conditioning: Impact on Clinical Outcome  Caroline Pical-Izard, Roberto.
Adoptive Therapy with T Cells/NK Cells
Cytomegalovirus Immune Reconstitution Occurs in Recipients of Allogeneic Hematopoietic Cell Transplants Irrespective of Detectable Cytomegalovirus Infection 
Efficacy and Safety of Ex Vivo Cultured Adult Human Mesenchymal Stem Cells (Prochymal™) in Pediatric Patients with Severe Refractory Acute Graft-Versus-Host.
T Cell Repertoire Development in XSCID Dogs Following Nonconditioned Allogeneic Bone Marrow Transplantation  William Vernau, Brian J. Hartnett, Douglas.
Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources  Christopher M. Walker,
Claudio G. Brunstein, Bruce R. Blazar, Jeffrey S
Quantity and Quality Reconstitution of NKG2A+ Natural Killer Cells Are Associated with Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation 
Lymphocyte Subset Recovery and Outcome after Autologous Hematopoietic Stem Cell Transplantation for Plasma Cell Myeloma  Jessica Rueff, Michael Medinger,
Use of Alefacept for Preconditioning in Multiply Transfused Pediatric Patients with Nonmalignant Diseases  Elizabeth O. Stenger, Kuang-Yueh Chiang, Ann.
A Radio-Resistant Perforin-Expressing Lymphoid Population Controls Allogeneic T Cell Engraftment, Activation, and Onset of Graft-versus-Host Disease in.
A CD4 Domain 1 CC′ Loop Peptide Analogue Enhances Engraftment in a Murine Model of Bone Marrow Transplantation with Sublethal Conditioning  Gabor Varadi,
Sarah Nikiforow, Jerome Ritz 
Correlation between the numbers of naive T cells infused with blood stem cell allografts and the counts of naive T cells after transplantation  Jan Storek,
A Novel Strategy in Managing Post-Liver Transplant Acute Graft-Versus-Host-Disease: The New Era (T)Rojan Horse  Zeyad Kanaan, MD, William Tse, MD, FACP 
Amotosalen-treated donor T cells have polyclonal antigen-specific long-term function without graft-versus-host disease after allogeneic bone marrow transplantation 
Prevention of Graft-versus-Host Disease by Adoptive T Regulatory Therapy Is Associated with Active Repression of Peripheral Blood Toll-Like Receptor 5.
Reconstitution of Interleukin-17–Producing T Helper Cells after Allogeneic Hematopoietic Cell Transplantation  Felix Bahr, Rebekka Wehner, Uwe Platzbecker,
Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host.
In Situ Activation and Expansion of Host Tregs: A New Approach to Enhance Donor Chimerism and Stable Engraftment in Major Histocompatibility Complex-Matched.
Immune Cell Subset Counts Associated with Graft-versus-Host Disease
Heterogeneous Clearance of Antithymocyte Globulin after CD34+-Selected Allogeneic Hematopoietic Progenitor Cell Transplantation  Irina Kakhniashvili,
B Cells and Transplantation: An Educational Resource
Reconstitution of Natural Killer Cell Receptor Repertoires after Unmanipulated HLA- Mismatched/Haploidentical Blood and Marrow Transplantation: Analyses.
Low Risk of Chronic Graft-versus-Host Disease and Relapse Associated with T Cell– Depleted Peripheral Blood Stem Cell Transplantation for Acute Myelogenous.
A Two-Step Approach to Myeloablative Haploidentical Transplantation: Low Nonrelapse Mortality and High Survival Confirmed in Patients with Earlier Stage.
Eva Guinan, Leo Luzmik, Rupert Handgretinger, Ann Woolfrey 
CTLA-4 Blockade following Relapse of Malignancy after Allogeneic Stem Cell Transplantation Is Associated with T Cell Activation But Not with Increased.
Persistence of host dendritic cells after transplantation is associated with graft-versus- host disease  Geoffrey W. Chan, Gullu Gorgun, Kenneth B. Miller,
Protective Immunity Transferred by Infusion of Cytomegalovirus-Specific CD8+ T Cells within Donor Grafts: Its Associations with Cytomegalovirus Reactivation.
CD3+/Tregs Ratio in Donor Grafts Is Linked to Acute Graft-versus-Host Disease and Immunologic Recovery after Allogeneic Peripheral Blood Stem Cell Transplantation 
What is quality in a transplant program?
Issues of Aging and Geriatric Medicine: Relevance to Cancer Treatment and Hematopoietic Reconstitution  William B. Ershler, Andrew S. Artz, Evan T. Keller 
T-Cell Receptor Vα Spectratype Analysis of a CD4-Mediated T-Cell Response against Minor Histocompatibility Antigens Involved in Severe Graft-versus-Host.
Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews  Emily C. Merkel, Sandra A. Mitchell,
Immune Reconstitution in Recipients of Photodepleted HLA-Identical Sibling Donor Stem Cell Transplantations: T Cell Subset Frequencies Predict Outcome 
A 2-Step Approach to Peripheral Blood Haploidentical Stem Cell Transplantation for Patients with Advanced High Risk Lymphomas  Adetokunbo Folashade Oluwasanjo,
Young Female Donors Do Not Increase the Risk of Graft-versus-Host Disease or Impact Overall Outcomes in Pediatric HLA-Matched Sibling Hematopoietic Stem.
A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation:
Reconstitution of T Cell Subset Repertoire Diversity following Multiple Antigen- Mismatched Bone Marrow Transplantation  Thea M. Friedman, Olga Azhipa,
Mammen Chandy  Biology of Blood and Marrow Transplantation 
Treatment versus Transplant for Challenging Hematologic Disorders
Prospective Monitoring of Tumor Necrosis Factor α and Interferon γ to Predict the Onset of Acute and Chronic Graft-versus-Host Disease after Allogeneic.
Higher Risk of Cytomegalovirus and Aspergillus Infections in Recipients of T Cell– Depleted Unrelated Bone Marrow: Analysis of Infectious Complications.
Sarah Nikiforow, Haesook T
A Phase I Study in Adults of Clofarabine Combined with High-Dose Melphalan as Reduced-Intensity Conditioning for Allogeneic Transplantation  Mark H. Kirschbaum,
Mary Eapen  Biology of Blood and Marrow Transplantation 
Correlation of Infused CD3+CD8+ Cells with Single-Donor Dominance after Double-Unit Cord Blood Transplantation  Filippo Milano, Shelly Heimfeld, Ted Gooley,
Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience  Andy I. Chen, Alex McMillan,
Optimal Donor Selection: Beyond HLA
Presentation transcript:

Antiviral Responses following L-Leucyl-L-Leucine Methyl Esther (LLME)-Treated Lymphocyte Infusions: Graft-versus-Infection without Graft-versus-Host Disease  Joanne Filicko-O'Hara, Dolores Grosso, Phyllis R. Flomenberg, Thea M. Friedman, Janet Brunner, William Drobyski, Andres Ferber, Irina Kakhniashvili, Carolyn Keever-Taylor, Bijoyesh Mookerjee, Julie-An Talano, John I. Wagner, Robert Korngold, Neal Flomenberg  Biology of Blood and Marrow Transplantation  Volume 15, Issue 12, Pages 1609-1619 (December 2009) DOI: 10.1016/j.bbmt.2009.08.020 Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 LLME depletion. Flow cytometry of product prior to LLME treatment shows the presence of NK (CD56 or 16+/CD3−) cells, and CD3+/CD8+ cells, and CD3+/CD4+ cells. However, following LLME treatment, cells that contain perforin, namely, the NK cells and a portion of CD8+ cells, are markedly depleted. The CD4 cell population is only minimally depleted in contrast (A). Following treatment with LLME, products showed adequate depletions of NK and CD8+ cells with a median 95.2% (range: 79.9-100) depletion of NK cells, 76.1% (range: 35.1-92.8) of CD3+/CD8+ cells, but only 31.0% (0-88.8) of CD3+/CD4+ cells (B). Biology of Blood and Marrow Transplantation 2009 15, 1609-1619DOI: (10.1016/j.bbmt.2009.08.020) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Reconstitution of perforin-positive cells. Following LLME DLI, a product containing perforin-negative cells, patients were able to reconstitute both perforin-negative and then perforin-positive cells. For the sample patient seen here, recovery of CD3+/CD4+ cells was apparent by day 37 after LLME DLI (A). Earlier time points were measured (B) showing recovery of the same populations of cells but at lower numbers. The recovery of NK cells heralded (third dot plot and third column) preceded the recovery of CD8 cells. Reconstitution of CD8 cells included both perforin-positive and perforin-negative cells and preceded the recovery of CD4-positive cells. Biology of Blood and Marrow Transplantation 2009 15, 1609-1619DOI: (10.1016/j.bbmt.2009.08.020) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Immune reconstitution following LLME DLI. Patients developed rapid and sustained reconstitution of lymphocyte subsets following LLME DLI. As shown in this sample patient, this included CD3+/CD4+, CD3+/CD8+, and CD3−/CD56 or 16+ cells (A) as well as both memory and naïve CD4 cells (B). In 1 patient who had not converted to 100% donor cells at the time he received LLME DLI, the recovery of memory CD4 cells was more prominent (C). Biology of Blood and Marrow Transplantation 2009 15, 1609-1619DOI: (10.1016/j.bbmt.2009.08.020) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Antiviral responses. Sample data are shown for 2 patients. In panels A and B, one sees the data from a patient who developed adenovirus hepatitis. Shortly after receiving the LLME DLI, he began to clear the adenovirus with a 10-fold drop in PCR titers by 11 days s/p DLI (113 days s/p HPCT), and complete resolution by 42 days s/p DLI (144 days s/p HPCT). This was associated with an adenovirus specific CD4 IFN-γ response that was evident at 147 and 175 days post-DLI. Sample from a second patient, who had developed CMV infection, is shown in panels C and D. Once again, the patient had rapid resolution of CMV PCR titers with a significant drop within 6 days and complete resolution by 20 days s/p DLI (68 days s/p HPCT). He was also found to have developed both a CMV-specific CD8 response (anti-A2 peptide) and CD4 response (CMV ag), but no response to adenovirus. Biology of Blood and Marrow Transplantation 2009 15, 1609-1619DOI: (10.1016/j.bbmt.2009.08.020) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 5 Vβ spectratyping. Representative histograms of Vβ spectratype analysis of the CD4+ T cells enriched from the peripheral blood of 1 of the patients/pairs. The repertoire complexity of the donor sample before LLME treatment (A), after LLME treatment (B), and reconstituting in the patient post-LLME DLI (C) exhibit similar levels of complexity. Biology of Blood and Marrow Transplantation 2009 15, 1609-1619DOI: (10.1016/j.bbmt.2009.08.020) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions